William Blair analyst Myles Minter has maintained their bullish stance on ARGX stock, giving a Buy rating on October 23.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Myles Minter has given his Buy rating due to a combination of factors including Argenx Se’s impressive financial performance and strategic growth initiatives. The company’s Vyvgart product line has significantly exceeded revenue expectations, with a notable year-over-year growth of 96% and a sequential increase of 19%. This strong performance across multiple indications and formulations has contributed to the stock’s positive market reaction, trading up by as much as 6% premarket.
Minter also highlights Argenx’s consistent profitability, marking its fifth consecutive profitable quarter, which has bolstered its cash reserves to $4.3 billion. The company’s strategic expansion into new therapeutic areas, such as the planned registrational study in Graves’ disease, further underscores its growth potential. These factors collectively support Minter’s optimistic outlook and Buy rating for Argenx Se.
In another report released on October 23, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $943.00 price target.